Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the devel...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-03-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2841647?pdf=render |